WAYNE, Pa., Nov. 1 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) announced today that Fred G. Choate was appointed to its Board
of Directors for a term extending until 2007.  The appointment, which fills an
existing vacancy on the Escalon Board of Directors, increased the Board to six
members.
    Mr. Choate, age 59, is an accomplished senior executive whose experience
has spanned a varied group of companies. He has been a Managing Member of
Atlantic Capital Funding LLC, a privately owned commercial finance company,
since 2002 and has been a Managing Member of Atlantic Capital Management LLC
since 2004.  Since 2003, Mr. Choate has served as the Chief Investment Officer
at Baltic-American Enterprise Fund, a not-for-profit corporation engaged in a
private investment program in the Baltic States that supports the development
of small-to-medium sized businesses. Additionally, he has served as a Managing
Member of Greater Philadelphia Venture Capital Corp. since 1992.  Mr. Choate
has served as a director of Parke Bank since 2003 and formerly served as a
director of Escalon Medical from 1998 to 2003.
    "We are delighted that Fred has rejoined our Board as a non-executive
Director," Richard J. DePiano, Escalon's Chairman and Chief Executive Officer,
commented. "His distinguished business career and wealth of experience will
provide a unique and invaluable perspective to Escalon."

    About Escalon
    Founded in 1987, Escalon develops, markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices.  Drew, which operates as a separate division, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology, as
well as veterinary hematology and blood chemistry.  Escalon seeks to utilize
strategic partnerships to help finance its development programs and is also
seeking acquisitions to further diversify its product line to achieve critical
mass in sales and take better advantage of the Escalon's distribution
capabilities.  Escalon has headquarters in Wayne, Pennsylvania and
manufacturing operations in Long Island, New York, New Berlin, Wisconsin,
Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.

    Note:  This press release contains statements that are considered forward-
looking under the Private Securities Litigation Reform Act of 1995, including
statements about Escalon's future prospects.  They are based on the Escalon's
current expectations and are subject to a number of uncertainties and risks,
and actual results may differ materially.  The uncertainties and risks include
whether Escalon is able to improve upon the operations of Escalon's business
units, including, the integration of Drew's operations, generate cash and
identify, finance and enter into business relationships and acquisitions,
integrate and leverage those business relationships and acquisitions,
uncertainties and risks related to new product development, commercialization,
manufacturing and market acceptance of new products, marketing acceptance of
existing products in new markets, the continuity of royalty revenue,
litigation and non-recurring expenses, research and development activities,
including failure to demonstrate clinical efficacy, delays by regulatory
authorities, scientific and technical advances by Escalon or third parties,
introduction of competitive products, third party reimbursement and physician
training as well as general economic conditions.  Further information about
these and other relevant risks and uncertainties may be found in Escalon's
report on Form 10-K, and its other filings with the Securities and Exchange
Commission, all of which are available from the Commission as well as other
sources.

Link to this page: